Cowen Remains Bullish Following Alexion Pharma's (ALXN) 3Q
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Alexion Reports Third Quarter 2015 Results
October 29, 2015 6:30 AM EDTSoliris® (eculizumab) Net Product Sales of $665.4 Million; Increased 20% Year-on-Year Despite 9% Currency Headwinds; 29% Volume Increase Year-on-Year -
- 2015 Non-GAAP EPS Guidance Increased to $4.92 to $4.97 -
Strensiq (asfotase alfa) Approved in the United States, European Union, Japan and Canada for Hypophosphatasia (HPP)
Kanuma (sebelipase alfa) Approved in the European Union for Lysosomal Acid Lipase Deficiency (LAL-D)
Completed Enrollment in Registration Trial of Eculizumab in Refractory MG and Progressed Registration Trials in Relapsing NMO and DGF
Advanced Complement and Metabolic Pipelines, Including ALXN 1210 and SBC-103
CHESHIRE, Conn.--(BUSINESS... More
